-
RISS 활용도 분석
-
일본/중국/유럽자료
-
최신/인기 학술자료
-
해외논문구매대행(E-DDS)
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Hyun-Wook (검색결과 11,775 건)
- 무료
- 기관 내 무료
- 유료
-
원저 : 허혈성 심질환이 의심되는 이식신 수혜자에서 시행한 관상동맥 조영술 소견과 관상동맥 폐쇄성 질환의 위험인자
김현욱(Hyun Wook Kim), 장제현(Jae Hyun Chang), 김현진(Hyun Jin Kim), 김형종(Hyung Jong Kim), 류동열(Dong Ryeol Ryu), 유태현(Tae Hyun Yoo), 김범석(Bum Suk Kim), 강신욱(Shin Wook Kang), 최규헌(Kyu Hun Choi), 이호영(Ho Yung Lee), 한대석(Dae Suk H) 대한이식학회 2003 Korean Journal of Transplantation Vol.17 No.2
-
-
-
P019 : Nonbullous neutrophilic dermatosis in patient with lupus nephritis
( Hyun Joo Lee ), ( Hyunju Jin ), ( Hyang Suk You ), ( Woo Haing Shim ), ( Jeong Min Kim ), ( Hoon Soo Kim ), ( Hyun Chang Ko ), ( Byung Soo Kim ), ( Moon Bum Kim ), ( Gun Wook Kim ) 대한피부과학회 2016 대한피부과학회 학술발표대회집 Vol.68 No.1
Neutrophilic dermatosis is a rare manifestation of systemic lupus erythematosus (SLE). Neutrophilic infiltrates of skin in lupus patients with bullous systemic lupus erythematosus (BSLE) and leukocytoclastic vasculitis are well documented. However, nonbullous neutrophilic lesions in patients with SLE have been rarely reported. A 56-year-old female patient with a 1-year history of lupus nephritis presented with multiple erythematous to brownish patches and plaques on both legs for 1 month. She was kept on regular follow-up for lupus nephritis without medications. Histopathologic evaluation showed perivascular and interstitial neutrophilic infiltration with leukocytoclasia in upper dermis. The neutrophilic infiltrate is not as dense as Sweet syndrome and there is an absence of papillary dermal edema. Based on clinicopathological findings, she was diagnosed as nonbullous neutrophilic dermatosis in patients with SLE. The lesions were improved with topical corticosteroid cream twice daily for 3months. Although precise classification of nonbullous neutrophilic dermatosis is uncertain, various clinical features have been reported. Through this unusual case, it is important to consider nonbullous neutrophilic dermatosis in the differential diagnosis of neutrophil mediated eruptions in patients with SLE.
-
-
-
-
( Hyun Suk Ahn ), ( Sun Hwa Cha ), ( Hwa Seon Koo ), ( Ju Youn Bae ), ( Ji Hee Yoo ), ( In Ok Song ), ( Hyun Kyoung Ahn ), ( Su Jin Hwang ), ( Dong Wook Park ), ( Kwang Moon Yang ) 대한산부인과학회 2011 Obstetrics & Gynecology Science Vol.54 No.7
We aimed to evaluate the effect of prednisolone (PDS) on natural killer cell (NK cell) cytolytic activity in vitro. Methods Blood samples from 74 patients with history of unexplained recurrent spontaneous abortion who elevated peripheral blood NK cell fraction were collected prospectively. Peripheral blood monocytes which containing NK cells were isolated and separated to three different tubes which containing target (K562) cells by the 50:1 effector to target (E:T) ratio. PDS or intravenous immunoglobulin (IVIG) was additionally added to 2 tubes for evaluate their suppressive effect. The percentage killing of target cells was recorded numerically by using flow cytometer and the values between groups were statistically analyzed. Results The mean target cell killing percentage was 40.5% in co-culture tube which was not added PDS or IVIG. In culture experiments which was added IVIG, the killing percentage is reduced to 37.7% which showed no significant differences compared to that of co-cultured tube which was not added PDS or IVIG. But, in experiments with added PDS, the killing percent was reduced to 19.5% and the difference was statistically significant ( P<0.001) compared to that of co-cultured tube which was not added PDS or IVIG. On comparing the reduction in killing percentage of target cells by PDS and IVIG, statistically significant reduction in the PDS coculture was noted ( P<0.005). Conclusion NK cell cytolytic activity is effectively down-regulated by using PDS in vitro. Moreover, the effect of PDS in down-regulation of NK cell cytolytic activity is seems to superior than that of IVIG. But, large scaled in vivo study is needed.
-
-
( Hyun Jung Kwon ), ( Seong-jun Seo ), ( Young Lip Park ), ( Jooyoung Roh ), ( Chun Wook Park ), ( Moon Bum Kim ), ( Gwang Seoung Choi ), ( Dong-ho Nahm ), ( Hyo Hyun Ahn ), ( Young Min Park ), ( Kwang Hoon Lee) 대한피부과학회 2017 대한피부과학회 학술발표대회집 Vol.69 No.2
Background: Dupilumab, a fully human anti-IL-4Rα mAb, inhibits signaling of IL-4/IL-13, key drivers of type 2/Th2-mediated diseases, such as AD/asthma. Objectives: We report efficacy and safety of dupilumab in Korean patients (pts) with moderate-to-severe AD in a randomized, placebo (PBO)-controlled, multinational phase 3 trial (SOLO 2: NCT02277769). Methods: Pts were randomized 1:1:1 to subcutaneous dupilumab 300mg every 2 weeks (wks; q2w), weekly (qw), or PBO qw, for 16 wks. Results: 708 pts were randomized; 80 were Korean. In the Korean population, more dupilumab-treated pts achieved Investigator's Global Assessment 0/1 vs PBO at Wk 16 (primary endpoint; q2w/qw vs PBO: 33.3%/33.3% vs 0.0%; both P=0.0018), ≥75% improvement in Eczema Area and Severity Index (29.6%/40.7% vs 7.7%; P=0.0764/P=0.0091) and peak pruritus numerical rating scale ≥4-point improvement from baseline at Wk 16 vs PBO (33.3%/34.6% vs 3.8%; P=0.0113/P=0.0109) (key secondary). Dupilumab also improved Patient Oriented Eczema Measure and Dermatology Life Quality Index vs PBO at Wk 16 (both P<0.01) (secondary). Adverse events (AEs) were reported in 12/27 (q2w) and 8/27 pts (qw) vs 17/26 pts (PBO), none were serious. AD was the most common AE, occurring less frequently in the dupilumab groups vs PBO (4/27 and 4/27 pts vs 16/26 pts). Conclusion: The efficacy and acceptable safety profile of dupilumab in Korean pts were generally consistent with the overall study population.
KCI
